Market news

PHVS, UNCY, BHVN, CYTK, KURA, GRCE, INSM, RARE, CELC, RCKT_________________________________________________BUY | 12-month price target $31 (+51%) | Lumvoa...

Viridian Therapeutics' (VRDN) Lumvoa is off to a "stronger start" than anticipated, RBC Capital Mark

Viridian Therapeutics aims to leverage its infrastructure for both Lumvoa and elegrobart, potentially improving franchise economics. Read more on VRDN.

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

WALTHAM, Mass., August 06, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026.

Tipranks Press Release.

Viridian Therapeutics (VRDN) has drawn fresh investor attention after recent trading left the stock at $19.08. Recent performance has been mixed across different periods, and the company’s business remains focused on therapies for serious and rare diseases. See our latest analysis for Viridian Therapeutics. At a share price of $19.08, Viridian Therapeutics reflects a mixed picture, with a 30 day share price return of 16.70% and a 90 day share price return of 28.23%, alongside a year to date...

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 affordable biotech stocks to buy right now. On June 30, Goldman Sachs increased its target price for Viridian Therapeutics Inc. (NASDAQ:VRDN) from $35 to $39, implying an adjusted upside potential in excess of 105% at the prevailing level. The firm maintained its Buy rating on the […]

Viridian Therapeutics stock has fallen 37.8% year to date, yet the valuation checks still point to the shares looking expensive rather than like a clear bargain. The year to date decline of 37.8% raises the question of whether the recent weakness has gone far enough to justify the current share price. Future revenue potential from Viridian Therapeutics' pipeline can support higher expectations, but the need to fund ongoing development and potential cash burn may weigh on what investors are...

With EPS growth for the next five years forecasted at 67.57%, Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 12 Best Quality Stocks to Buy and Hold for the Next Decade. On June 30, Wedbush analyst Laura Chico raised the firm’s price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $43 from $32 while maintaining an Outperform rating following […]